PMDA Drug Approval Process: A Complete English Guide for 2026

What is PMDA?

The Pharmaceuticals and Medical Devices Agency (PMDA) is Japan's regulatory authority responsible for evaluating and approving pharmaceuticals, medical devices, and regenerative medicine products. Established in 2004, PMDA operates under the jurisdiction of the Ministry of Health, Labour and Welfare (MHLW)and functions as Japan's equivalent of the U.S. FDA or Europe's EMA.

PMDA has three core functions: review (evaluating applications for marketing authorization), safety (post-market surveillance and adverse event monitoring), and relief (compensating patients for adverse drug reactions). The agency employs approximately 1,000 staff, including around 400 reviewers who handle drug evaluations.

Japan's pharmaceutical market was valued at approximately $84 billion in 2025, making it the third-largest single market globally after the United States and China. For any global pharmaceutical company with commercial ambitions in Asia, understanding the PMDA approval process is not optional — it is essential.

Types of Drug Applications

PMDA accepts several categories of drug applications, each with distinct regulatory pathways and data requirements:

New Drug Application (NDA)

For novel chemical entities or new molecular entities not previously approved in Japan. This is the most comprehensive application type, requiring full preclinical and clinical data packages. In FY2024, PMDA approved 42 new molecular entities through this pathway, with a median total review time of approximately 12 months.

Biologics License Application (BLA)

For biological products including monoclonal antibodies, vaccines, blood products, and gene therapies. BLAs require additional characterization data, including detailed manufacturing process descriptions and comparability studies. The review process closely mirrors the NDA pathway but with additional emphasis on CMC (Chemistry, Manufacturing, and Controls) data.

Generic Drug Application

For drugs that are bioequivalent to an already-approved reference product in Japan. Generic applications require bioequivalence studies but not full clinical trials. PMDA reviews approximately 400-500 generic drug applications per year. Japan's generic penetration rate has been rising steadily, reaching roughly 80% by volume in 2025, driven by government policies to reduce healthcare costs.

Biosimilar Application

For biological products that are highly similar to an approved reference biologic. Japan was one of the early adopters of biosimilar regulation, approving its first biosimilar in 2009. Biosimilar applications require comparative analytical, preclinical, and clinical studies. As of 2025, over 40 biosimilars have been approved in Japan.

Supplemental Applications

For changes to already-approved products, including new indications, new dosage forms, changes in manufacturing processes, or updated labeling. Supplemental applications (known as partial change applications in Japan) follow an abbreviated review process.

The Approval Process Step by Step

The PMDA drug approval process follows a structured sequence. Here is each stage, from earliest engagement to final marketing authorization:

Step 1: Pre-Application Consultation (Taimenjodan)

Before filing a formal application, companies are strongly encouraged to engage in pre-application consultations with PMDA. These face-to-face meetings (known as taimenjodan) are conducted on a fee basis and cover topics such as clinical trial design, data requirements, and regulatory strategy. PMDA offers several types of consultations:

• Protocol consultations — Advice on clinical trial design and endpoints before initiating pivotal studies
• Pre-NDA consultations — Discussion of the overall data package and submission strategy
• Quality consultations — CMC and manufacturing process guidance
• GMP/QMS consultations — Manufacturing facility compliance discussions

These consultations are not mandatory, but they are highly recommended. Companies that skip pre-consultation often face delays during the review process due to data gaps or misaligned expectations. Each consultation costs between JPY 1.1 million to JPY 6.8 million (approximately $7,000 to $45,000 USD) depending on the type and scope.

Step 2: Clinical Trials (CTN Filing)

To conduct clinical trials in Japan, sponsors must file a Clinical Trial Notification (CTN)with PMDA at least 30 days before initiating the study. Unlike the FDA's IND process, the CTN follows a notification system rather than an approval system — the trial may proceed 30 days after filing unless PMDA raises objections.

Japan is a member of the ICH (International Council for Harmonisation), so clinical trial data generated under ICH-GCP guidelines in other countries can be accepted. However, PMDA may require bridging studies or additional Japanese patient data to account for potential ethnic differences in drug response. The ICH E5 guideline on ethnic factors is particularly important for foreign sponsors planning to use non-Japanese clinical data.

Step 3: NDA Submission

Once clinical development is complete, the sponsor submits a New Drug Application (NDA) to PMDA. The application follows the Common Technical Document (CTD) format, as mandated by ICH. As of April 2026, all submissions must use the eCTD v4.0 format.

The application must include Module 1 (administrative and prescribing information, in Japanese), Module 2 (summaries), Module 3 (quality/CMC data), Module 4 (nonclinical study reports), and Module 5 (clinical study reports). PMDA charges an application review fee ranging from JPY 2.3 million to JPY 40 million+ depending on the product type and review category.

Step 4: PMDA Review

PMDA conducts a comprehensive review that includes both scientific/medical review and regulatory review. The process involves:

• Team assignment — A review team of 5-8 members is assigned, including medical officers, pharmacologists, statisticians, and CMC reviewers
• Questions and responses — PMDA issues questions to the applicant (typically 2-4 rounds). All correspondence is in Japanese
• Expert discussion — For complex or novel products, PMDA convenes an expert advisory meeting to discuss key issues
• Review report drafting — PMDA prepares a detailed review report (Shinsa Hokoku-sho) summarizing its evaluation

Step 5: GMP Inspection

In parallel with the NDA review, PMDA conducts GMP (Good Manufacturing Practice) compliance inspections of all manufacturing sites. This is a mandatory step — no drug can be approved without GMP clearance for every manufacturing facility involved, including overseas sites. Inspections typically take 3-5 days per site and cover:

• Manufacturing process validation
• Quality control systems and laboratory practices
• Document management and change control procedures
• Facility and equipment qualification

For overseas facilities, PMDA inspectors may conduct on-site inspections or accept reports from foreign regulatory authorities under mutual recognition agreements. Japan has MRA arrangements with the EU for GMP inspections, which can streamline the process for EU-based manufacturers.

Step 6: MHLW Approval

After PMDA completes its review and issues a favorable review report, the file is forwarded to the Pharmaceutical Affairs and Food Sanitation Council (PAFSC), an advisory body to MHLW. PAFSC reviews the PMDA report and may convene additional expert discussions. Upon PAFSC endorsement, the Minister of Health, Labour and Welfare grants final marketing approval.

Step 7: NHI Price Listing

Unlike many other markets, Japan has a universal health insurance system that covers prescription drugs. After marketing approval, companies must negotiate inclusion on the National Health Insurance (NHI) drug price list before commercial launch. The Central Social Insurance Medical Council (Chuikyo) determines the reimbursement price. This process typically takes 60-90 days after approval. Without NHI listing, a drug effectively cannot be sold in the Japanese market.

Review Timelines

PMDA review timelines vary depending on the product type and review designation. Here are the current benchmarks:

It is worth noting that these timelines measure only the PMDA review period — not the total time from submission to market launch. When you factor in GMP inspection, PAFSC deliberation, MHLW approval, and NHI price negotiation, the total time from NDA filing to commercial availability is typically 15-20 months for standard reviews and 10-14 months for priority or accelerated pathways.

PMDA has steadily improved its review efficiency over the past decade. In 2015, the median review time for new molecular entities was approximately 15 months. By 2024, that figure had been reduced to under 12 months, putting PMDA roughly on par with the FDA's standard review timeline.

Key Differences from the FDA Process

While PMDA and FDA share the same ICH foundation, there are critical differences that regulatory teams must account for:

• Language — PMDA requires Module 1 and key summaries in Japanese. All reviewer correspondence is conducted in Japanese. The FDA operates entirely in English.
• Clinical trial notification vs. IND approval — Japan uses a 30-day notification system (CTN), while the FDA requires formal IND approval. In practice, the CTN system can be faster for trial initiation.
• Bridging studies — PMDA may require bridging studies to demonstrate that foreign clinical data is applicable to the Japanese population (per ICH E5). The FDA does not have an equivalent ethnic bridging requirement.
• GMP inspection timing — PMDA conducts GMP inspections as part of the NDA review process (in parallel). FDA GMP inspections (pre-approval inspections) are also conducted during review but follow different scheduling and scope.
• Pricing integration— Japan's NHI price listing is a mandatory post-approval step before commercial launch. In the U.S., drug pricing is a separate commercial decision not directly tied to the regulatory approval process.
• Advisory committee structure — PMDA uses the PAFSC as a post-review advisory step. The FDA convenes Advisory Committee meetings during the review process itself.
• Marketing Authorization Holder (MAH) — Japan requires a domestic MAH. Foreign companies must either establish a Japanese subsidiary or partner with a Japanese company to serve as the MAH.

Required Documents and Language Requirements

The document requirements for a PMDA submission follow the ICH CTD structure but with Japan-specific additions:

CTD Module Requirements

• Module 1 (Administrative) — Must be entirely in Japanese. Includes the application form, proposed labeling (package insert), risk management plan (RMP), and patent certification
• Module 2 (Summaries) — Quality Overall Summary (QOS), Nonclinical Overview, Clinical Overview, and Nonclinical/ Clinical Summaries. PMDA requires Japanese-language summaries in addition to English versions
• Modules 3-5 (Data) — Can be submitted in English with Japanese summaries

Japan-Specific Documents

• CTD-J (Japan-specific Module 1) — Contains Japan-specific administrative documents not covered in the standard CTD
• Interview Form (IF) — A detailed product information document unique to Japan, typically 50-100 pages, used by pharmacists and physicians
• Risk Management Plan (J-RMP)— Japan's version of the risk management plan, which must include specific post-marketing surveillance protocols
• Re-examination application data — Required for the post-marketing re-examination period (discussed below)

Translation and Language Strategy

The language requirement is one of the most significant operational challenges for foreign companies filing in Japan. Key considerations:

• All Module 1 documents, including the proposed package insert, must be in Japanese
• Module 2 summaries require Japanese versions
• All PMDA correspondence (questions, meeting minutes, review reports) is conducted in Japanese
• Technical and scientific translation for pharmaceutical regulatory documents requires specialized expertise — general translation services are insufficient
• Budget $200,000-$500,000+ for translation costs on a typical NDA filing, depending on the size of the data package

SAKIGAKE Designation and Conditional Early Approval

Japan has introduced several expedited pathways to accelerate access to innovative therapies:

SAKIGAKE Designation

Introduced in 2015 and codified into law in 2019, the SAKIGAKE (pioneer) designation is designed to ensure that innovative drugs developed in Japan reach Japanese patients first. Products eligible for SAKIGAKE designation must meet these criteria:

• Novel mechanism of action
• Intended for a serious or life-threatening disease with high unmet medical need
• Significant clinical improvement expected over existing treatments
• Development aimed at Japan as the first market for approval

Benefits of SAKIGAKE designation include a 6-month target review time (versus 12 months standard), prioritized pre-application consultation, a dedicated PMDA review team (concierge consultation), and potential for extended re-examination period (up to 10 years of data exclusivity). Since 2015, approximately 30+ products have received SAKIGAKE designation.

Conditional Early Approval System

Introduced in 2017, this pathway allows PMDA to grant approval based on limited clinical data when:

• The disease is serious with no adequate treatments available
• The drug is expected to have significant efficacy, but it would be difficult to conduct large-scale clinical trials in Japan (e.g., due to small patient populations)

Products approved under this pathway are subject to strict post-marketing conditions, including mandatory all-case surveillance or specified use-results surveys. The approval may be revoked if post-marketing data does not confirm the expected benefit-risk profile.

Orphan Drug Designation

Japan's orphan drug system targets diseases affecting fewer than 50,000 patients in Japan. Incentives include priority review, reduced review fees (up to 27% reduction), tax credits for R&D expenses, and an extended re-examination period of up to 10 years. In FY2024, approximately 15-20% of all NDA approvals carried orphan drug designation.

Tips for Foreign Companies

For regulatory teams at non-Japanese pharmaceutical companies, here are practical recommendations based on common challenges:

1. Establish a Japanese presence early — You need a domestic Marketing Authorization Holder. Whether through a Japanese subsidiary, a joint venture, or a licensing partner, this decision affects every aspect of your regulatory strategy. Start this process at least 2-3 years before your planned filing date.
2. Engage PMDA pre-consultation— Do not skip this step. PMDA's pre-application consultation is one of the most constructive and transparent regulatory interactions in the world. PMDA reviewers will tell you exactly what data they need.
3. Plan for bridging studies from the start — If your global clinical program does not include Japanese sites, assume you will need a bridging study. Include Japanese patient enrollment in your global Phase III design if possible — this is the most efficient approach.
4. Invest in Japanese regulatory writing capability — The language barrier is real and consequential. Having in-house or dedicated agency support for Japanese regulatory writing is not a luxury — it is a necessity.
5. Understand the NHI pricing process— Your market access strategy must account for Japan's price-setting mechanism. Drug pricing in Japan is formulaic, not negotiation-based. The reference pricing methodology and premium categories (e.g., innovation premium, pediatric premium) should inform your global pricing strategy.
6. Plan for post-marketing obligations— Japan's re-examination system requires sponsors to collect and submit post-marketing data over a period of 4-10 years after approval. This is a legally binding commitment, not optional pharmacovigilance. Budget and staff accordingly.
7. Leverage PMDA's international initiatives — PMDA offers international consultation meetings in English for overseas sponsors considering filing in Japan. These are available even before CTN filing and can clarify regulatory expectations early.
8. Monitor PMDA approval trends — Understanding which drugs PMDA has recently approved, what review questions were raised, and what conditions were imposed provides invaluable intelligence for your own submission strategy.

How PharmaLens Can Help

Navigating the PMDA approval process requires access to reliable, English-language regulatory intelligence. PMDA publishes a wealth of information — review reports, approval conditions, meeting minutes — but almost entirely in Japanese.

This is exactly the problem PharmaLens solves. Our platform monitors every PMDA approval, translates and structures the review reports, and makes the data searchable and comparable. Regulatory teams use PharmaLens to benchmark review timelines, analyze approval conditions by therapeutic area, identify reviewer concerns, and prepare stronger submissions.

Whether you are filing your first NDA in Japan or managing a portfolio of approved products, having real-time access to structured PMDA data in English eliminates one of the biggest barriers to operating in the Japanese market.

References

• PMDA Official Website (English)
• PMDA Review Process Overview
• PMDA Pre-Application Consultation Services
• Ministry of Health, Labour and Welfare (MHLW)
• ICH Guidelines — Including ICH E5 (Ethnic Factors)

Source: PMDA Website. This article is for informational purposes only and does not constitute regulatory advice.